Assessment of Baseline Cd4 Cell Count Testing, Contrimoxazole Uptake and Its Barriers among HIV- Positive Patients at Bugando Medical Centre
Material type:
TextPublisher number: Phone: +255 28 298 3384 Fax: +255 28 298 3386 Email: vc@bugando.ac.tz Website: www.bugando.ac.tz Language: English Language: Kiswahili Publication details: Mwanza, Tanzania: Catholic University of Health and Allied Sciences [CUHAS – Bugando] : ©2023Description: 51 Pages; Includes References and AppendiciesSubject(s): Summary: Abstract:
Background: HIV is the virus that attacks body immune system specifically CD4 cells and thus lower the CD4 cell count. CD4 testing has the role to play in the context of diagnosing opportunistic infections and managing some aspects of treatment. If the CD4 cell count is <350 we initiate co-trimoxazole prophylaxis. CTX is used as the prophylaxis and treatment for different opportunistic infections affecting HIV patients. The study aim on assessing the baseline CD4 cell count testing and uptake of cotrimoxazole and its barriers among HIV positive patients at BMC.So that these barriers could be removed.
Objective: To assess baseline CD4 cell count testing and cotrimoxazole uptake and its barriers among HIV positive patients at BMC
Methodology: A prospective cross sectional hospital based study was conducted using a structured closed end questionnaires. In which eligible patients to use cotrimoxazole prophylaxis at BMC was interviewed for a period of one month from September to October. The study data were collected, recorded, and analyzed using computer program SPSS version 20.
Results: 240 participants were selected to take part in the study where all had been test for CD4 cell count. The majority were presenting with symptoms of HIV/AIDS and were in clinical stage 4 during data collection (90.8% and 58.3% respectively). The barriers of uptake of co-trimoxazole use identified were presence of side effects after using co-trimoxazole (19.2%), lack of free provision of the drug in health facilities (2.9%) as well as long procedure to take the drug which was seen as a reason in 6.6% of the participants. The longest duration that most of the participants identified as going without using co-trimoxazole was a week (58.3%
Conclusion: Majority of the clients were tested for CD4 count, and among those who tested majority were found in WHO clinical stage four. According to this study not all clients who eligible to receive cotrimoxazole prophylaxis were receiving it and the barriers has been side effect of the drug, long procedure to get drug and luck of free provision of drugs in the facilities.
Abstract:
Background: HIV is the virus that attacks body immune system specifically CD4 cells and thus lower the CD4 cell count. CD4 testing has the role to play in the context of diagnosing opportunistic infections and managing some aspects of treatment. If the CD4 cell count is <350 we initiate co-trimoxazole prophylaxis. CTX is used as the prophylaxis and treatment for different opportunistic infections affecting HIV patients. The study aim on assessing the baseline CD4 cell count testing and uptake of cotrimoxazole and its barriers among HIV positive patients at BMC.So that these barriers could be removed.
Objective: To assess baseline CD4 cell count testing and cotrimoxazole uptake and its barriers among HIV positive patients at BMC
Methodology: A prospective cross sectional hospital based study was conducted using a structured closed end questionnaires. In which eligible patients to use cotrimoxazole prophylaxis at BMC was interviewed for a period of one month from September to October. The study data were collected, recorded, and analyzed using computer program SPSS version 20.
Results: 240 participants were selected to take part in the study where all had been test for CD4 cell count. The majority were presenting with symptoms of HIV/AIDS and were in clinical stage 4 during data collection (90.8% and 58.3% respectively). The barriers of uptake of co-trimoxazole use identified were presence of side effects after using co-trimoxazole (19.2%), lack of free provision of the drug in health facilities (2.9%) as well as long procedure to take the drug which was seen as a reason in 6.6% of the participants. The longest duration that most of the participants identified as going without using co-trimoxazole was a week (58.3%
Conclusion: Majority of the clients were tested for CD4 count, and among those who tested majority were found in WHO clinical stage four. According to this study not all clients who eligible to receive cotrimoxazole prophylaxis were receiving it and the barriers has been side effect of the drug, long procedure to get drug and luck of free provision of drugs in the facilities.
There are no comments on this title.
Click on an image to view it in the image viewer